M&A / Deals Eli Lilly doubles down on in vivo with $7bn Kelonia buyout Pharmaceutical TechnologyLilly now has a lentiviral and LNP-based platform for in vivo delivery under its belt, which could broaden the company's chance of success.M&A / DealsGene Therapy PlatformRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) Pharmaceutical Technology Lilly now has a lentiviral and LNP-based platform for in vivo delivery under its belt, which could broaden the company’s chance of success. M&A / DealsGene Therapy PlatformRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Asahi Kasei acquires German company AicurisNext: Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
